TechSeeker Profile

Transgene S.A
Profile last edited on: 1/24/2017

NO Business Identifier is currently available for this company.
TS Type
Small firm: Foreign
Status
N/A
Year Founded
1979
Last Involved Year
N/A

Key People / Management

  Jean-Marc Balloul -- New Business Development Director

Location Information

11 Rue De Molsheim Cedex
Strasbourg, FR 67082
   33 3 88 27 91 00
   www.transgene.fr

Public Profile

Transgene S.A., a biopharmaceutical company, engages in the discovery and development of gene-based therapeutic vaccines and immunotherapy products for the treatment of cancer and infectious diseases. The company’s products primarily include TG 4001/R3484, an immunotherapy targeting anti-infectious for human papilloma virus-associated pathologies, which completed Phase IIa trials; TG 4010, a cancer vaccine primarily for non small cell lung cancer, which is in Phase IIb trials; TG 1042, an immune enhancement gene therapy for cutaneous B-cell lymphoma, which is in Phase II trials; TG 4040, an anti-infectious therapeutic vaccine for chronic hepatitis C infection, which is in Phase I trials; and TG 4023, a preclinical suicide gene candidate for the treatment of 5-FU-sensitive tumors. It also offers a package of services relating to molecular biology, development, and biomanufacturing that include design and construction of new vaccines; development and/or adaptation of production process; development and/or adaptation of quality control assays; production and control of starting material for pharmaceutical and clinical development; and manufacturing material for clinical trials. Transgene S.A. has collaboration agreements with Roche, Association Francaise contre les Myopathies, and MIRUS; manufacturing and subcontracting agreements with International AIDS Vaccine Initiative, Innogenetics, Agence Nationale de Recherche contre le SIDA, Institut National de la Sante et de la Recherche Medicale, and EUROVACC; and licensing agreements with Merck, Imperial Cancer Research Technology, Ajinomoto, Aventis, and Cayla. The company was founded in 1979 and is based in Strasbourg, France. Transgene S.A. is a subsidiary of Merieux Alliance.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Headquartered
France
Employment
241
Revenue
N/A
Public/Private
Publicly Traded
Stock Info
Paris : TNG
Received SBIR $$
No

Techseeker firm in the news

There are no news available.